StockIQpro
NASDAQ:AVTX

Avalo Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Avalo Therapeutics, Inc.'s revenue fell 86.6% in fiscal 2025 to $59,000 while operating margin fell to −123601.7%, its lowest in 10 years. The diluted share count rose 78.8%.Summary generated from Avalo Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$59,000
Revenue growth−86.6%
Revenue, 5-yr CAGR−61.2%
Gross marginn/a
Operating margin−123601.7%
Net margin−132642.4%
ROICn/a
Return on equity−72.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+78.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue518200
Operating income−82−37−27−69−73
Net income−84−42−32−35−78
Free cash flow−71−27n/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations